Here is how our Uncle Leo ended the question about the potential for a reverse split:
"So, let's see what the clinical data will be before we bring up this question about reverse split, which is not on the table."
The implication is clear -- if clincial data isn't enough to uplist, then and only then will the company think about a reverse split.
The last part of the sentence -- which is not on the table -- speaks to the present time. Not the future if the first pieces of clincial data can't raise share price to a level necessary to uplist.
Market Data 
Markets 
AI
